All articles tagged with #pluvicto
Novartis announced that its drug Pluvicto showed significant benefits in delaying disease progression in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, based on interim results from the Phase III PSMAddition trial, and plans to submit for regulatory review after presenting the data.
Novartis' therapy for metastatic prostate cancer, Pluvicto, has shown potential benefits as a treatment before chemotherapy, according to Phase 3 data presented at the European Society for Medical Oncology. The trial enrolled patients with metastatic prostate cancer who had previously taken an androgen receptor pathway inhibitor, and the results highlight the effectiveness of radiation-delivering cancer therapies. Novartis' investment in this field is attracting interest from other pharmaceutical companies.